Here's why Moderna stock soared 125% during the first 6 months of 2021

The COVID-19 vaccine maker has been well rewarded for coming up with a stopgap solution as quickly as it did.

| More on:
share price soaring

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of biopharma Moderna (NASDAQ: MRNA) advanced 124.9% during the first half of this year, according to S&P Global Market Intelligence. The rally extends gains made since early 2020, when the company emerged as a COVID-19 vaccine contender, and then delivered on that promise later in the year.

So what

It's a name that needs little in the way of an introduction. Moderna joins Johnson & Johnson (NYSE: JNJ), Novavax (NASDAQ: NVAX), and a partnership between Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) as the core suppliers of the vaccines aimed at curbing the coronavirus contagion. Moderna's mRNA-1273 was approved by the FDA for emergency use in December of last year, though investors were willing to reward the company before and after that green light. And well they should. Product revenue for the developmental company grew from essentially nothing a year earlier to $1.7 billion for the three-month stretch ending in March, with all of it consisting of COVID vaccine sales. In the meantime, the company has continued to expand on the potential of mRNA-1273 as well as move forward with trials of other vaccine and treatment candidates. It also has other trials underway, such as testing of its mRNA technology as a means of treating cancer, autoimmune disease, and cardiovascular disease -- though for the foreseeable future, evolving strains of COVID will keep the organization busy.

Now what

It's tempting to step into (or stick with) one of the market's hottest biotech stocks that's performing well for all the right reasons. The pandemic could be with us for a while -- perhaps permanently if new strains keep surfacing -- and Moderna's answer thus far appears to be the least problematic. J&J's vaccine has been linked to the development of Guillain-Barre syndrome, while Pfizer's might lead to heart inflammation in rare cases. Moderna's mRNA solution can also cause the same myocarditis, although it's highly effective, and if nothing else, it's increasingly available in an environment where something is better than nothing. With shares up nearly 900% since the coronavirus outbreak went worldwide last year, though, existing shareholders may want to start thinking about an exit plan. While Moderna has provided a beacon of hope, its effort and potential are not only well publicized and fully priced into shares, but they might also be more than priced in. Even the usually aggressive analyst community agrees that shares are only worth on the order of $177 right now, while the stock is trading at a frothy $238.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Moderna right now?

Before you buy Moderna shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Moderna wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 5 December 2024

James Brumley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Man looking at digital holograms of graphs, charts, and data.
International Stock News

Why Alphabet's 'challenging' 2025 may benefit the stock as it pushes AI innovation

Alphabet employees have been told to be ready for an important -- and challenging -- year ahead.

Read more »

A businessman holds a bolt of energy in both hands, indicating a share price rise in ASX energy companies
International Stock News

Microsoft CEO Satya Nadella just said something that could be terrible news for Nvidia but great news for this commodity stock in 2025

The winners and losers in the artificial intelligence market could change rapidly in this fast-evolving space.

Read more »

a woman holds out an electric vehicle charger with a satisfied look on her face behind cool sunglasses.
International Stock News

Why Tesla stock dropped to start the New Year

Investors are driving the Tesla share price down at the start of 2025. But why?

Read more »

woman watching Netflix and flicking the channel
International Stock News

Should you buy Netflix stock before January 6?

2024 was a milestone year for Netflix, hallmarked by the company's foray into live sporting events.

Read more »

A head shot of legendary investor Warren Buffett speaking into a microphone at an event.
International Stock News

Prediction: Warren Buffett's Berkshire Hathaway stock will outperform the S&P 500 in 2025

The legendary investor has a proven track record.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
International Stock News

Should investors unfriend Meta Platforms stock in 2025?

Investors may want to consider whether they want to foster a friendship with Meta. Or is now is the time…

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
International Stock News

Top 10 US shares that Aussie investors bought most in 2024

US shares had a magnificent year...

Read more »

a business person checks his mobile phone outside a Wall Street office with an American flag and other business people in the background.
International Stock News

How Long Will the "Trump Bump" for the Stock Market Last? Here's What History Shows.

Historical patterns from past presidencies can provide insight into how long the market's momentum might last—and what investors should prepare…

Read more »